Pfizer Inc. (NYSE:PFE) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 11.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 291,268 shares of the biopharmaceutical company’s stock after selling 36,742 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Pfizer were worth $7,727,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Swedbank AB increased its position in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares during the period. Financial Advocates Investment Management boosted its stake in Pfizer by 5.5% during the third quarter. Financial Advocates Investment Management now owns 44,909 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 2,361 shares in the last quarter. United Asset Strategies Inc. grew its holdings in Pfizer by 7.1% during the third quarter. United Asset Strategies Inc. now owns 32,274 shares of the biopharmaceutical company’s stock worth $934,000 after acquiring an additional 2,141 shares during the period. Reston Wealth Management LLC bought a new stake in Pfizer in the third quarter worth about $83,000. Finally, Aspen Wealth Strategies LLC lifted its holdings in Pfizer by 22.0% in the 3rd quarter. Aspen Wealth Strategies LLC now owns 10,207 shares of the biopharmaceutical company’s stock valued at $295,000 after acquiring an additional 1,843 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PFE. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Guggenheim reiterated a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of PFE opened at $26.43 on Friday. The company has a market capitalization of $149.78 billion, a PE ratio of 18.74, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company’s 50 day moving average price is $26.35 and its 200 day moving average price is $27.34. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the company posted $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.51%. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.